WEBULL
Releases
TPTX
76.01
0.00%
0.00
  • All
  • Financials
  • Insiders
More
Webull provides the latest Turning Point Therapeutics (TPTX) stock and general news. This information may help you make smarter investment decisions.
About TPTX
Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing and developing therapies that target genetic drivers of cancer to improve the lives of patients. It develops a macrocycle platform from which it designs its pipeline of small, compact tyrosine kinase inhibitors (TKIs). The TKIs generated from its drug discovery platform address unmet needs in TKI naive and resistance settings. The Company’s drug candidate, repotrectinib (TPX-0005), is in Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with NTRK+ or ALK+ advanced solid tumors. Its multi-cohort Phase II registrational portion of TRIDENT-1 is ongoing at sites in North America, Europe and the Asia-Pacific regions. The Company’s pipeline includes multi-targeted kinase inhibitors: TPX-0046 (a novel RET inhibitor), Elzovantinib (TPX-0022) (a novel MET/CSF1R/SRC inhibitor) and TPX-0131.